Nanopharm Limited

POWER SEARCH PRICING

SOLUTIONS

nanopharm limited Company Information

Company Number

04371441

Next Accounts

Sep 2025

Directors

Gwenaelle Rowe-Joseph

Christopher Hall

View All

Shareholders

aptargroup uk holdings ltd

Group Structure

View All

Industry

Manufacture of pharmaceutical preparations

Registered Address

5 bruntcliffe avenue, morley, leeds, LS27 0LL

Website

www.nanopharm.co.uk

nanopharm limited Estimated Valuation

£10.3m

Pomanda estimates the enterprise value of NANOPHARM LIMITED at £10.3m based on a Turnover of £7.5m and 1.37x industry multiple (adjusted for size and gross margin).

Edit your figures and get a professional valuation report.

Nanopharm Limited is a live company located in leeds, LS27 0LL with a Companies House number of 04371441. It operates in the manufacture of pharmaceutical preparations sector, SIC Code 21200. Founded in February 2002, it's largest shareholder is aptargroup uk holdings ltd with a 100% stake. Nanopharm Limited is a mature, mid sized company, Pomanda has estimated its turnover at £7.5m with healthy growth in recent years.

View Sample

Upgrade for unlimited company reports & a free credit check

Pomanda's financial health check has awarded Nanopharm Limited a 2.5 rating. We use a traffic light system to show it exceeds the industry average on 3 measures and has 7 areas for improvement. Company Health Check FAQs

Health Rating2.5out of 5

3 Strong

1 Regular

7 Weak

Size

annual sales of £7.5m, make it smaller than the average company (£35m)

Growth

3 year (CAGR) sales growth of 8%, show it is growing at a faster rate (4.5%)

EXPORT

Nanopharm Limited's latest turnover from December 2023 is £7.5 million and the company has net assets of £5 million. According to their latest financial statements, Nanopharm Limited has 74 employees and maintains cash reserves of £54.2 thousand as reported in the balance sheet.

Data source: Companies House, Pomanda Estimates

	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Jun 2019	Sep 2018	Sep 2017	Sep 2016	Sep 2015	Sep 2014	Sep 2013	Sep 2012	Sep 2011	Sep 2010	Sep 2009
Turnover	7,486,864	5,865,408	7,128,602	5,999,910	10,839,103	7,323,433	5,710,826	1,535,768	1,754,872	864,114	555,482	729,177	1,156,441	651,402	207,827
Other Income Or Grants
Cost Of Sales	5,302,236	3,276,952	4,576,892	3,707,946	6,388,788	4,078,627	3,185,029	823,010	1,025,411	547,135	351,464	454,051	776,955	423,116	134,994
Gross Profit	2,184,628	2,588,456	2,551,710	2,291,965	4,450,316	3,244,806	2,525,797	712,758	729,460	316,978	204,018	275,127	379,486	228,285	72,834
Admin Expenses	3,104,282	2,399,648	1,311,092	2,258,350	1,079,653	1,443,621	2,231,401	388,121	139,121	-69,386	10,674	199,045	44,946	381,445	198,839	-547,168
Operating Profit	-919,654	188,808	1,240,618	33,615	3,370,663	1,801,185	294,396	324,637	590,339	386,364	193,344	76,082	334,540	-153,160	-126,005	547,168
Interest Payable	8,487	53
Interest Receivable	34,351	15,539	3,924	1,281	4,330	6,824	3,757	1,359	902	995	868	1,380	1,263	876	902	390
Pre-Tax Profit	-893,790	204,294	1,244,542	34,896	3,374,994	1,808,009	298,153	325,996	591,241	387,359	194,211	77,462	335,803	-152,284	-125,103	547,558
Tax	182,170	-114,745	-236,463	-6,630	-641,249	-343,522	-56,649	-61,939	-118,248	-77,472	-40,784	-17,816	-80,593			-153,316
Profit After Tax	-711,620	89,549	1,008,079	28,266	2,733,745	1,464,487	241,504	264,057	472,993	309,887	153,427	59,646	255,210	-152,284	-125,103	394,242
Dividends Paid
Retained Profit	-711,620	89,549	1,008,079	28,266	2,733,745	1,464,487	241,504	264,057	472,993	309,887	153,427	59,646	255,210	-152,284	-125,103	394,242
Employee Costs	3,674,654	2,572,402	3,258,196	2,500,277	2,366,048	1,556,492	940,729	408,000	431,810	169,361	131,030	158,138	195,611	124,585	39,642
Number Of Employees	74	59	49	39	36	26	18	8	10	4	3	4	5	3	1
EBITDA*	-436,661	436,176	1,467,222	202,828	3,447,798	1,892,996	432,762	399,597	652,013	447,648	236,087	135,083	368,846	-139,799	-110,539	560,247

* Earnings Before Interest, Tax, Depreciation and Amortisation

	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Jun 2019	Sep 2018	Sep 2017	Sep 2016	Sep 2015	Sep 2014	Sep 2013	Sep 2012	Sep 2011	Sep 2010	Sep 2009
Tangible Assets	4,273,426	2,925,047	2,363,121	1,081,346	1,010,884	879,859	709,292	723,579	645,754	643,169	539,127	243,835	192,562	75,529	83,572	72,275
Intangible Assets	150,682	193,036
Investments & Other
Debtors (Due After 1 year)
Total Fixed Assets	4,424,108	3,118,083	2,363,121	1,081,346	1,010,884	879,859	709,292	723,579	645,754	643,169	539,127	243,835	192,562	75,529	83,572	72,275
Stock & work in progress
Trade Debtors	1,676,794	1,108,806	891,753	618,930	2,097,534	1,449,514	1,291,746	321,404	428,082	173,801		124,115			29,610	300,000
Group Debtors	90,930	1,322,017	1,224,271	1,347,583	1,291,743
Misc Debtors	1,394,799	918,159	671,246	384,907	126,497	257,697	122,211	34,994	19,392	21,056
Cash	54,224	670,751	1,339,469	1,799,729	762,068	1,427,067	392,694	609,276	478,177	243,432	154,486	192,656	359,341	145,829	204,660	155,954
misc current assets								3,388
total current assets	3,216,747	4,019,733	4,126,739	4,151,149	4,277,842	3,134,278	1,806,651	969,062	925,651	438,289	154,486	316,771	359,341	145,829	234,270	455,954
total assets	7,640,855	7,137,816	6,489,860	5,232,495	5,288,726	4,014,137	2,515,943	1,692,641	1,571,405	1,081,458	693,613	560,606	551,903	221,358	317,842	528,229
Bank overdraft	455,227
Bank loan
Trade Creditors	209,639	199,737	72,683	81,351	230,678	255,259	80,006	39,928	41,454	57,607	108,465	128,885	179,828	104,493	48,693	133,983
Group/Directors Accounts	648,270	273,926	2,322		201,575
other short term finances
hp & lease commitments					13,453	58,005	75,347
other current liabilities	1,087,964	530,607	485,603	384,256	98,064	246,938	404,832	20,628	161,923	128,816
total current liabilities	2,401,100	1,004,270	560,608	465,607	543,770	560,202	560,185	60,556	203,377	186,423	108,465	128,885	179,828	104,493	48,693	133,983
loans
hp & lease commitments
Accruals and Deferred Income
other liabilities
provisions	218,057	400,228	285,483	131,198	137,532	115,769	82,079
total long term liabilities	218,057	400,228	285,483	131,198	137,532	115,769	82,079
total liabilities	2,619,157	1,404,498	846,091	596,805	681,302	675,971	642,264	60,556	203,377	186,423	108,465	128,885	179,828	104,493	48,693	133,983
net assets	5,021,698	5,733,318	5,643,769	4,635,690	4,607,424	3,338,166	1,873,679	1,632,085	1,368,028	895,035	585,148	431,721	372,075	116,865	269,149	394,246
total shareholders funds	5,021,698	5,733,318	5,643,769	4,635,690	4,607,424	3,338,166	1,873,679	1,632,085	1,368,028	895,035	585,148	431,721	372,075	116,865	269,149	394,246

	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Jun 2019	Sep 2018	Sep 2017	Sep 2016	Sep 2015	Sep 2014	Sep 2013	Sep 2012	Sep 2011	Sep 2010	Sep 2009
Operating Activities
Operating Profit	-919,654	188,808	1,240,618	33,615	3,370,663	1,801,185	294,396	324,637	590,339	386,364	193,344	76,082	334,540	-153,160	-126,005	547,168
Depreciation	440,639	229,704	226,604	169,213	77,135	91,811	138,366	74,960	61,674	61,284	42,743	59,001	34,306	13,361	15,466	13,079
Amortisation	42,354	17,664
Tax	182,170	-114,745	-236,463	-6,630	-641,249	-343,522	-56,649	-61,939	-118,248	-77,472	-40,784	-17,816	-80,593			-153,316
Stock
Debtors	-186,459	561,712	435,850	-1,164,354	2,101,817	293,254	1,057,559	-91,076	252,617	194,857	-124,115	124,115		-29,610	-270,390	300,000
Creditors	9,902	127,054	-8,668	-149,327	150,672	175,253	40,078	-1,526	-16,153	-50,858	-20,420	-50,943	75,335	55,800	-85,290	133,983
Accruals and Deferred Income	557,357	45,004	101,347	286,192	-306,768	-157,894	384,204	-141,295	33,107	128,816
Deferred Taxes & Provisions	-182,171	114,745	154,285	-6,334	55,453	33,690	82,079
Cash flow from operations	317,056	46,522	1,041,873	1,491,083	604,089	1,307,269	-175,085	285,913	298,102	253,277	298,998	-57,791	363,588	-54,389	74,561	240,914
Investing Activities
capital expenditure			-1,508,379	-239,675	-378,727	-262,378	-124,079	-152,785	-64,259	-165,326	-338,035	-110,274	-151,339	-5,318	-26,763	-85,354
Change in Investments
cash flow from investments			-1,508,379	-239,675	-378,727	-262,378	-124,079	-152,785	-64,259	-165,326	-338,035	-110,274	-151,339	-5,318	-26,763	-85,354
Financing Activities
Bank loans
Group/Directors Accounts	374,344	271,604	2,322	-201,575	201,575
Other Short Term Loans
Long term loans
Hire Purchase and Lease Commitments				-13,453	-61,894	-17,342	75,347
other long term liabilities
share issue							90								6	4
interest	25,864	15,486	3,924	1,281	4,330	6,824	3,757	1,359	902	995	868	1,380	1,263	876	902	390
cash flow from financing	400,208	287,090	6,246	-213,747	144,011	-10,518	79,194	1,359	902	995	868	1,380	1,263	876	908	394
cash and cash equivalents
cash	-616,527	-668,718	-460,260	1,037,661	369,374	1,034,373	-216,582	131,099	234,745	88,946	-38,170	-166,685	213,512	-58,831	48,706	155,954
overdraft	455,227
change in cash	-1,071,754	-668,718	-460,260	1,037,661	369,374	1,034,373	-216,582	131,099	234,745	88,946	-38,170	-166,685	213,512	-58,831	48,706	155,954

Very Low Risk70 - 100

Low Risk50 - 70

Moderate Risk30 - 50

High Risk20 - 30

Very High Risk0 - 20

Get a comprehensive credit check for nanopharm limited. Get real-time insights into nanopharm limited's credit score, group structure and payment trends.

From as little as £6.99

This will not impact your credit rating!

View Credit Report Sample

Perform a competitor analysis for nanopharm limited by selecting its closest rivals, whether from the MANUFACTURING sector, other mid companies, companies in LS27 area or any other competitors across 12 key performance metrics.

NANOPHARM LIMITED group structure

Nanopharm Limited has no subsidiary companies.

Ultimate parent company

APTARGROUP INC

#0012644

APTARGROUP UK HOLDINGS LIMITED

04613135

2 parents

NANOPHARM LIMITED

04371441

NANOPHARM LIMITED Shareholders

aptargroup uk holdings ltd

100%

Nanopharm Limited currently has 3 directors. The longest serving directors include Gwenaelle Rowe-Joseph (Jun 2019) and Mr Christopher Hall (Jun 2019).

officer	country	age	start	end	role
Gwenaelle Rowe-Joseph	France	61 years	Jun 2019	-	Director
Mr Christopher Hall	England	58 years	Jun 2019	-	Director
Mr Guillaume Brouet	France	58 years	Jun 2019	-	Director

P&L

December 2023

turnover

7.5m

+28%

operating profit

-919.7k

-587%

gross margin

29.2%

-33.88%

turnover

Turnover, or revenue, is the amount of sales generated by a company within the financial year.

Balance Sheet

December 2023

net assets

-0.12%

total assets

7.6m

+0.07%

cash

54.2k

-0.92%

net assets

Total assets minus all liabilities

Similar Companies

hipra uk and ireland limited

3.5

aguettant limited

3.5

ptc therapeutics, limited

lab 21 healthcare limited

pcca limited

company number

04371441

Type

Private limited with Share Capital

industry

21200 - Manufacture of pharmaceutical preparations

incorporation date

February 2002

ultimate parent company

APTARGROUP INC

previous names

N/A

address

5 bruntcliffe avenue, morley, leeds, LS27 0LL

A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.

We did not find charges/mortgages relating to nanopharm limited.

When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.

Click to start generating capital raising & share issue transactions for NANOPHARM LIMITED. This can take several minutes, an email will notify you when this has completed.

nanopharm limited Company Information

nanopharm limited Estimated Valuation

nanopharm limited Estimated Valuation

nanopharm limited Estimated Valuation

Nanopharm Limited Overview

Nanopharm Limited Health Check

NANOPHARM LIMITED financials

nanopharm limited Credit Report and Business Information

Nanopharm Limited Competitor Analysis

nanopharm limited Ownership

nanopharm limited directors

nanopharm limited company details

nanopharm limited Charges & Mortgages

nanopharm limited Capital Raised & Share Issues BETA

nanopharm limited Companies House Filings - See Documents